Quantcast

Latest Trubion Stories

2010-04-05 15:00:00

SEATTLE, April 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at the BioCentury and Thomson Reuters Future Leaders in the Biotech Industry conference to be held at the Millennium Broadway Hotel & Conference Center, 145 West 44th St. in New York City. Michelle Burris, senior vice president and chief operating officer, and Dr. Ken Mohler, senior vice president and chief scientific officer, are scheduled to...

2010-03-15 15:00:00

SEATTLE, March 15 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its fourth quarter and year ended Dec. 31, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Fourth-Quarter and Year-Ended 2009 Financial Results Revenue for the fourth quarter of 2009 was $5.2 million compared with $4.3 million for the fourth quarter of 2008. Revenue for the year ended Dec. 31, 2009, was $18.0 million compared with $16.5...

2010-03-11 15:00:00

SEATTLE, March 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that it will participate in the upcoming 10th Annual Life Science Innovation Northwest (LSINW) conference to be held at the Bell Harbor International Convention Center, 2211 Alaskan Way, Seattle, on March 16 - 17, 2010. Michelle Burris, senior vice president and chief operating officer, will present a company overview on March 16 at 1:45 p.m. PT, and will also take part in a panel...

2010-03-08 15:00:00

SEATTLE, March 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2009, after the close of market on March 15, 2010. The company's earnings conference call will take place March 15, 2010, at 2 p.m. Pacific Time, 5 p.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Both live events will be available for viewing on Trubion's website...

2010-01-11 07:00:00

SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus...

2010-01-06 15:00:00

SEATTLE, Jan. 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at OneMedForum 2010 to be held at the Sir Francis Drake Hotel, 450 Powell Street / Union Square in San Francisco. Michelle Burris, senior vice president and chief operating officer, is scheduled to present on Tuesday, Jan. 12 at 8:30 a.m. PT. The presentation will be available on http://www.trubion.com. (Logo:...

2009-12-07 15:00:00

SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corp. (Nasdaq: FACT) today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the...

2009-11-16 15:00:00

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that Peter Thompson, M.D., FACP, President, Chief Executive Officer, Chairman of the Board of Directors and co-founder of Trubion, has retired from the company to pursue other interests. Steven Gillis, Ph.D., former Lead Director of Trubion's Board of Directors, has been appointed Executive Chairman of the Board and Acting President. Dr. Thompson has entered into a consulting agreement...

2009-11-11 15:00:00

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana. The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating...

2009-11-05 15:00:00

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its third quarter and nine months ended Sept. 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Third Quarter and Nine Months 2009 Financial Results Revenue for the third quarter and nine months ended Sept. 30, 2009, was $4.5 million and $12.8 million, respectively, compared with $3.8 million and $12.2 million, respectively, in 2008....


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related